|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RPL21 |
Gene summary for RPL21 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RPL21 | Gene ID | 6144 |
| Gene name | ribosomal protein L21 | |
| Gene Alias | HYPT12 | |
| Cytomap | 13q12.2 | |
| Gene Type | protein-coding | GO ID | GO:0002181 | UniProtAcc | P46778 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6144 | RPL21 | GSM4909282 | Human | Breast | IDC | 1.80e-32 | -2.56e-01 | -0.0288 |
| 6144 | RPL21 | GSM4909285 | Human | Breast | IDC | 1.46e-08 | 1.64e-01 | 0.21 |
| 6144 | RPL21 | GSM4909286 | Human | Breast | IDC | 5.12e-21 | 2.10e-01 | 0.1081 |
| 6144 | RPL21 | GSM4909287 | Human | Breast | IDC | 1.58e-20 | -3.58e-01 | 0.2057 |
| 6144 | RPL21 | GSM4909290 | Human | Breast | IDC | 1.84e-13 | -2.56e-01 | 0.2096 |
| 6144 | RPL21 | GSM4909292 | Human | Breast | IDC | 8.30e-09 | 3.02e-01 | 0.1236 |
| 6144 | RPL21 | GSM4909293 | Human | Breast | IDC | 8.73e-40 | -2.58e-01 | 0.1581 |
| 6144 | RPL21 | GSM4909296 | Human | Breast | IDC | 5.06e-29 | 2.63e-01 | 0.1524 |
| 6144 | RPL21 | GSM4909297 | Human | Breast | IDC | 6.12e-103 | 4.35e-01 | 0.1517 |
| 6144 | RPL21 | GSM4909298 | Human | Breast | IDC | 2.94e-09 | 1.64e-01 | 0.1551 |
| 6144 | RPL21 | GSM4909299 | Human | Breast | IDC | 1.63e-13 | 1.81e-01 | 0.035 |
| 6144 | RPL21 | GSM4909301 | Human | Breast | IDC | 1.02e-44 | -3.65e-01 | 0.1577 |
| 6144 | RPL21 | GSM4909304 | Human | Breast | IDC | 2.92e-53 | -3.55e-01 | 0.1636 |
| 6144 | RPL21 | GSM4909305 | Human | Breast | IDC | 4.41e-06 | 1.28e-01 | 0.0436 |
| 6144 | RPL21 | GSM4909307 | Human | Breast | IDC | 8.26e-18 | -2.10e-01 | 0.1569 |
| 6144 | RPL21 | GSM4909308 | Human | Breast | IDC | 6.32e-23 | -2.22e-01 | 0.158 |
| 6144 | RPL21 | GSM4909311 | Human | Breast | IDC | 3.75e-12 | 7.52e-02 | 0.1534 |
| 6144 | RPL21 | GSM4909312 | Human | Breast | IDC | 1.81e-09 | 1.69e-01 | 0.1552 |
| 6144 | RPL21 | GSM4909315 | Human | Breast | IDC | 8.48e-08 | -1.65e-01 | 0.21 |
| 6144 | RPL21 | GSM4909319 | Human | Breast | IDC | 1.56e-24 | -4.19e-01 | 0.1563 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000218114 | Breast | IDC | cytoplasmic translation | 82/1434 | 148/18723 | 2.60e-52 | 1.48e-48 | 82 |
| GO:000218124 | Breast | DCIS | cytoplasmic translation | 82/1390 | 148/18723 | 2.21e-53 | 1.25e-49 | 82 |
| GO:000218110 | Cervix | CC | cytoplasmic translation | 96/2311 | 148/18723 | 4.87e-51 | 2.91e-47 | 96 |
| GO:000218115 | Cervix | HSIL_HPV | cytoplasmic translation | 86/737 | 148/18723 | 3.97e-82 | 1.91e-78 | 86 |
| GO:000218125 | Cervix | N_HPV | cytoplasmic translation | 42/534 | 148/18723 | 2.61e-30 | 1.19e-26 | 42 |
| GO:0002181 | Colorectum | AD | cytoplasmic translation | 109/3918 | 148/18723 | 3.40e-43 | 2.13e-39 | 109 |
| GO:00021811 | Colorectum | SER | cytoplasmic translation | 102/2897 | 148/18723 | 1.38e-48 | 8.49e-45 | 102 |
| GO:00021812 | Colorectum | MSS | cytoplasmic translation | 108/3467 | 148/18723 | 1.78e-47 | 1.11e-43 | 108 |
| GO:00021813 | Colorectum | MSI-H | cytoplasmic translation | 100/1319 | 148/18723 | 1.50e-79 | 8.31e-76 | 100 |
| GO:00021814 | Colorectum | FAP | cytoplasmic translation | 76/2622 | 148/18723 | 3.31e-27 | 2.03e-23 | 76 |
| GO:000218116 | Endometrium | AEH | cytoplasmic translation | 104/2100 | 148/18723 | 1.01e-64 | 6.07e-61 | 104 |
| GO:000218117 | Endometrium | EEC | cytoplasmic translation | 104/2168 | 148/18723 | 2.53e-63 | 1.52e-59 | 104 |
| GO:000218127 | Esophagus | HGIN | cytoplasmic translation | 108/2587 | 148/18723 | 1.70e-60 | 1.02e-56 | 108 |
| GO:0002181111 | Esophagus | ESCC | cytoplasmic translation | 135/8552 | 148/18723 | 4.17e-32 | 2.65e-29 | 135 |
| GO:00021817 | Liver | NAFLD | cytoplasmic translation | 93/1882 | 148/18723 | 1.44e-55 | 8.41e-52 | 93 |
| GO:000218112 | Liver | Cirrhotic | cytoplasmic translation | 120/4634 | 148/18723 | 2.95e-47 | 1.85e-43 | 120 |
| GO:000218122 | Liver | HCC | cytoplasmic translation | 132/7958 | 148/18723 | 9.09e-33 | 5.76e-30 | 132 |
| GO:00021818 | Lung | IAC | cytoplasmic translation | 85/2061 | 148/18723 | 3.11e-43 | 1.85e-39 | 85 |
| GO:000218113 | Lung | AIS | cytoplasmic translation | 85/1849 | 148/18723 | 5.48e-47 | 3.19e-43 | 85 |
| GO:000218123 | Lung | AAH | cytoplasmic translation | 64/613 | 148/18723 | 1.74e-55 | 7.99e-52 | 64 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0301022 | Liver | Cirrhotic | Ribosome | 127/2530 | 167/8465 | 2.12e-35 | 7.06e-33 | 4.35e-33 | 127 |
| hsa0517122 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
| hsa0301032 | Liver | Cirrhotic | Ribosome | 127/2530 | 167/8465 | 2.12e-35 | 7.06e-33 | 4.35e-33 | 127 |
| hsa0517132 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
| hsa0301042 | Liver | HCC | Ribosome | 128/4020 | 167/8465 | 7.32e-15 | 2.23e-13 | 1.24e-13 | 128 |
| hsa0517142 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
| hsa0301052 | Liver | HCC | Ribosome | 128/4020 | 167/8465 | 7.32e-15 | 2.23e-13 | 1.24e-13 | 128 |
| hsa0517152 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
| hsa0517116 | Lung | IAC | Coronavirus disease - COVID-19 | 102/1053 | 232/8465 | 5.89e-34 | 1.91e-31 | 1.27e-31 | 102 |
| hsa0301016 | Lung | IAC | Ribosome | 76/1053 | 167/8465 | 1.18e-26 | 1.91e-24 | 1.27e-24 | 76 |
| hsa0517117 | Lung | IAC | Coronavirus disease - COVID-19 | 102/1053 | 232/8465 | 5.89e-34 | 1.91e-31 | 1.27e-31 | 102 |
| hsa0301017 | Lung | IAC | Ribosome | 76/1053 | 167/8465 | 1.18e-26 | 1.91e-24 | 1.27e-24 | 76 |
| hsa0517123 | Lung | AIS | Coronavirus disease - COVID-19 | 98/961 | 232/8465 | 2.82e-34 | 9.14e-32 | 5.85e-32 | 98 |
| hsa0301023 | Lung | AIS | Ribosome | 76/961 | 167/8465 | 2.61e-29 | 4.22e-27 | 2.70e-27 | 76 |
| hsa0517133 | Lung | AIS | Coronavirus disease - COVID-19 | 98/961 | 232/8465 | 2.82e-34 | 9.14e-32 | 5.85e-32 | 98 |
| hsa0301033 | Lung | AIS | Ribosome | 76/961 | 167/8465 | 2.61e-29 | 4.22e-27 | 2.70e-27 | 76 |
| hsa0301043 | Lung | AAH | Ribosome | 63/348 | 167/8465 | 3.21e-45 | 8.95e-43 | 7.19e-43 | 63 |
| hsa0517143 | Lung | AAH | Coronavirus disease - COVID-19 | 70/348 | 232/8465 | 9.07e-43 | 1.27e-40 | 1.02e-40 | 70 |
| hsa0301053 | Lung | AAH | Ribosome | 63/348 | 167/8465 | 3.21e-45 | 8.95e-43 | 7.19e-43 | 63 |
| hsa0517153 | Lung | AAH | Coronavirus disease - COVID-19 | 70/348 | 232/8465 | 9.07e-43 | 1.27e-40 | 1.02e-40 | 70 |
| Page: 1 2 3 4 5 6 7 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RPL21 | SNV | Missense_Mutation | novel | c.278T>G | p.Ile93Ser | p.I93S | P46778 | protein_coding | deleterious(0.02) | benign(0.242) | TCGA-D8-A140-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin+cyclophosphamid | SD |
| RPL21 | SNV | Missense_Mutation | c.45N>A | p.Phe15Leu | p.F15L | P46778 | protein_coding | deleterious(0.04) | possibly_damaging(0.539) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| RPL21 | SNV | Missense_Mutation | c.95N>A | p.Arg32Gln | p.R32Q | P46778 | protein_coding | tolerated(0.26) | benign(0.02) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD | |
| RPL21 | SNV | Missense_Mutation | novel | c.107A>C | p.Lys36Thr | p.K36T | P46778 | protein_coding | deleterious(0.03) | possibly_damaging(0.673) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| RPL21 | SNV | Missense_Mutation | novel | c.222T>G | p.Ile74Met | p.I74M | P46778 | protein_coding | deleterious(0.01) | probably_damaging(0.938) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RPL21 | SNV | Missense_Mutation | c.148N>C | p.Lys50Gln | p.K50Q | P46778 | protein_coding | deleterious(0.02) | possibly_damaging(0.818) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
| RPL21 | SNV | Missense_Mutation | c.388C>T | p.Arg130Cys | p.R130C | P46778 | protein_coding | tolerated(0.18) | benign(0.007) | TCGA-B5-A11Y-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| RPL21 | SNV | Missense_Mutation | novel | c.345N>C | p.Lys115Asn | p.K115N | P46778 | protein_coding | deleterious(0.04) | benign(0.061) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| RPL21 | SNV | Missense_Mutation | c.322N>T | p.Arg108Cys | p.R108C | P46778 | protein_coding | tolerated(0.16) | benign(0.001) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| RPL21 | SNV | Missense_Mutation | c.431N>C | p.Asn144Thr | p.N144T | P46778 | protein_coding | tolerated(0.07) | benign(0.082) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |